Deutsche Bank Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Expert Weigh In on DECISION

July 10, 2012 10:48 AM EDT Send to a Friend
Get Alerts ONXX Hot Sheet
Price: $124.70 --0%

Rating Summary:
    11 Buy, 12 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 29 | Down: 45 | New: 4
Trade ONXX Now!
Join SI Premium – FREE
Deutsche Bank reiterates a 'Buy' on Onyx Pharmaceuticals (NASDAQ: ONXX) price target of $77.00.

Analyst, Navdeep Singh, said, "In preparation for the phase 3 DECISION results, we hosted an expert call for clients. DECISION is evaluating Nexavar vs. placebo in points w/ thyroid cancer that is refractory to radioactive iodine. Given our conversation with expert & prior phase 2 data, we believe this opportunity is underappreciated. Onyx expects top-line data in H2:12. We expect data in Q3:12. Since investors do not assign much value to DECISION, we see limited downside risk into top-line."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $67.24 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Deutsche Bank

Add Your Comment